Parallel vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
Paris France YC W24 AI medical coding and admin agents for hospitals; $3.5M seed Apr 2025 led by Frst with Paul Meta/McKinsey and Thomas CTO adapting to fragmented hospital software competing with Nuance for healthcare admin automation.
About
Parallel is a Paris, France-based AI healthcare administration platform — backed by Y Combinator (W24) with $3.5 million in seed funding in April 2025 led by Frst with Y Combinator — providing hospitals and healthcare providers with vertical AI agents that automate time-consuming administrative tasks, starting with medical coding, using generative AI that streamlines hospital operations, improves billing accuracy, and reduces the administrative workload on medical staff — allowing clinicians to focus on patient care rather than documentation and coding compliance. Founded in 2024 by Paul Lafforgue (Meta/McKinsey background) and Thomas Sohet (CTO), with Yago as a co-founder, Parallel's 6-person Paris team designs AI agents that adapt to real-world hospital environments and fragmented software stacks.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.